

Military Rehabilitation and Compensation (MRCA Pharmaceutical Benefits Scheme) Amendment (Additional Community Supply Support Payment) Determination 2024

I, Andrew Kefford, a delegate of the Minister for Veterans’ Affairs, approve for the purposes of subsection 286(6) of the *Military Rehabilitation and Compensation Act 2004*, the variations made by the Military Rehabilitation and Compensation Commission of the *MRCA Pharmaceutical Benefits Scheme* in the following instrument.

Dated 1 November 2024

Andrew Kefford PSM  
Deputy Secretary, Policy & Programs

Department of Veterans’ Affairs

The Military Rehabilitation and Compensation Commission makes the following instrument.

Dated 30 October 2024

The Seal of the

Military Rehabilitation and

Compensation Commission

was affixed to this instrument

in the presence of:

|  |  |
| --- | --- |
| Mark Brewer | Gwen Cherne |
| AM CSC and Bar |  |
| Acting Deputy President  Repatriation Commission | Member |
| Kahlil Fegan | Greg Vines |
| DSC AM |  |
| Member | Member |
| Rear Admiral Sonya Bennett |  |
| AM RAN |  |
| Member |  |

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments 2

MRCA Pharmaceutical Benefits Scheme 2

1 Name

This instrument is the *Military Rehabilitation and Compensation (MRCA Pharmaceutical Benefits Scheme) Amendment (Additional Community Supply Support Payment) Determination 2024*.

2 Commencement

This instrument commences, or is taken to have commenced, at the same time as the commencement of the instrument made under paragraph 98B(1)(b) of the *National Health Act 1953*.

3 Authority

This instrument is made under subsection 286(5) of the *Military Rehabilitation and Compensation Act 2004*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

MRCA Pharmaceutical Benefits Scheme

1. At the end of part 5

*insert*

**32A Additional community supply support payment**

1. In this section:

*increased maximum quantity*, of a *Pharmaceutical benefit*, means the maximum quantity or number of units of the benefit, or of a *pharmaceutical item* in the benefit, that may, in 1 prescription, be directed to be supplied on any 1 occasion, for a *relevant purpose*, under and in accordance with this *Scheme* or the *MRCA Treatment Principles*, part 5.7.

***increased maximum quantity prescription*** means a prescription directing the supply, on any 1 occasion, of the *increased maximum quantity* of a *Pharmaceutical benefit*.

*NHA* means the *National Health Act 1953*.

*NHA instrument* means the instrument made under paragraph 98B(1)(b) of the *NHA*.

***relevant purpose***, for a *Pharmaceutical benefit*, means a purpose, mentioned in the *PBS Schedule* or *RPBS Schedule* in relation to the benefit, thatincludes the phrase “The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient”.

*Schedule equivalent*—a *Pharmaceutical benefit* is *Schedule equivalent* to another *Pharmaceutical benefit* if the *PBS Schedule* or *RPBS Schedule* states that the benefits are equivalent.

1. The *Commission* is to pay an amount of money (an ***ACSS payment***)to a *Community Pharmacist* for each supply by the pharmacist of a *Pharmaceutical benefit*:
2. on or after 1 April 2024; and
3. under, and in accordance with, the *Scheme* or the *MRCA Treatment Principles*, part 5.7.

unless the supply is a supply mentioned in paragraph 5(a), (b), (c), (d), (e) or (f) of the *NHA instrument*.

1. If an *ACSS payment* is payable for a supply, the amount of the payment is:
2. if subsection (4) or (5) applies to the supply—the amount mentioned in paragraph 6(1)(b) of the *NHA instrument*; or
3. in any other case—the amount mentioned in paragraph 6(1)(a) of the *NHA instrument*.
4. This subsection applies to a supply of a *Pharmaceutical benefit* to an *Eligible Person* for which an *ACSS payment* is payable if:
5. the supply is made upon an *increased maximum quantity prescription* directing the supply of:
6. the benefit; or
7. another *Pharmaceutical benefit* that is *Schedule equivalent* to the benefit; and
8. the supply is of the *increased maximum quantity* of the benefit.
9. This subsection applies to a supply of a *Pharmaceutical benefit* to an *Eligible Person* for which an *ACSS payment* is payable if:
10. the supply is made in accordance with section 16A; and
11. the immediately preceding supply to the person of the benefit, or of another *Pharmaceutical benefit* that is *Schedule equivalent* to the benefit, was made upon an *increased maximum quantity prescription* directing the supply of:
12. the benefit; or
13. another *Pharmaceutical benefit* that is *Schedule equivalent* to the benefit; and
14. both the supplies mentioned in paragraphs (a) and (b) are of the *increased maximum quantity* of the relevant *Pharmaceutical benefit*.